السرطانات المقاومة للعلاج

Cancer cells develop drug resistance through four main strategies. First, they inhibit drug activation by mutating enzymes required to activate drugs like Cytosine arabinoside. Second, they modify drug targets so medications cannot bind effectively. Third, they increase drug efflux by overexpressing transporters like MDR1 that pump drugs out of cells. Fourth, they elevate DNA damage response by overexpressing repair enzymes like MGMT that reverse drug-induced damage.

Genetic instability allows cancer cells to acquire resistance mutations rapidly. When initial drug treatment eliminates most tumor cells, a small fraction of resistant mutant cells called persisters survive and divide to form a new tumor. All cells in this new tumor are now resistant to the original drug, causing therapeutic failure. This rapid mutation rate enables cancer cells to continually evolve new resistance mechanisms.

The cancer stem cell (CSC) model explains resistance through quiescent cells with increased DNA repair efficiency, altered cell cycle parameters, or overexpression of anti-apoptotic properties and drug transporters. In this model, drug resistance arises from intrinsic or acquired resistance of accumulating cancer stem cells rather than all cancer cells within a tumor. These specialized cells survive treatment and drive tumor relapse.

The Environment-mediated drug resistance (EMDR) model describes how cancer cells interact with their surrounding tumor microenvironment to enter a quiescent or dormant state and escape drugs. Inside this protective zone, cancer cells undergo genetic changes until acquiring a resistant phenotype. Once the drug is withdrawn, these cells can relapse and regrow, explaining why treatment may initially succeed but ultimately fail.

The MDR1 gene encodes an ATP-binding cassette (ABC) transporter that pumps lipophilic drugs out of cancer cells. Resistant cancer cells often overexpress this transporter, reducing intracellular drug concentration below therapeutic levels. Because MDR1 transporters can efflux a broad range of chemotherapy drugs, their overexpression results in multidrug resistance, making cancer cells resistant to multiple different medications simultaneously.

MGMT (O6-methylguanine methyltransferase) is an enzyme that resistant tumor cells overexpress to survive alkylating drug treatment. These drugs methylate guanine nucleotides into O6-methylguanine, which causes mismatch mutations. MGMT converts the modified base back to guanine before mutations pass to the next generation, thus negating the drug's action and allowing cancer cells to survive treatment.

Tumors contain various cancer cell subpopulations, each with distinct genetic fingerprints. Some cells may have pre-existing mutations or acquire new mutations conferring drug resistance. Under therapeutic pressure, cancer cells obey Darwinian evolution, and only the most adaptive and resistant cells survive and multiply to take over susceptible subpopulations. This genetic diversity accelerates the emergence of treatment-resistant tumors.